Realtime | Geld | Brief | Zeit |
---|---|---|---|
11,400 | 13,200 | 11:22 |
EQS-News: Formycon AG: Formycon publiziert Ergebnisse der analytischen Studie zur Vergleichbarkeit des Biosimilarkandidaten FYB206 mit Keytruda® in der Fachzeitschrift Drugs in R&D | EQS-News: Formycon AG
/ Schlagwort(e): Wissenschaftl. Publikation/Studienergebnisse
Formycon publiziert Ergebnisse der analytischen Studie zur Vergleichbarkeit des Biosimilarkandidaten... ► Artikel lesen |
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy | Original-Research: Formycon AG - from First Berlin Equity Research GmbH 01.10.2024 / 17:05 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer is... ► Artikel lesen |
Formycon: FYB202 mit FDA-Zulassung und früherem US-Launchtermin; mwb research bestätigt KAUFEN | Formycon hat die FDA-Zulassung für FYB202 erhalten, dem Biosimilar zu Johnson & Johnsons Stelara, welches das dritte von der FDA zugelassene Biosimilar des Unternehmens darstellt. Dies folgt auf die... ► Artikel lesen |
Onto Innovation Reports 2024 Third Quarter Results | WILMINGTON, Mass.--(BUSINESS WIRE)--Onto Innovation Inc. (NYSE: ONTO) ("Onto Innovation," "Onto," or the "Company") today announced financial results for the third fiscal quarter of 2024.
Third... ► Artikel lesen |
Onto Innovation Reports 2024 Second Quarter Results | WILMINGTON, Mass.--(BUSINESS WIRE)--Onto Innovation Inc. (NYSE: ONTO) ("Onto Innovation," "Onto," or the "Company") today announced financial results for the second fiscal quarter of 2024.
Second... ► Artikel lesen |
Onto Innovation Reports 2024 First Quarter Results | WILMINGTON, Mass.--(BUSINESS WIRE)--Onto Innovation Inc. (NYSE: ONTO) ("Onto Innovation," "Onto," or the "Company") today announced financial results for the first fiscal quarter of 2024.
First... ► Artikel lesen |
RIBER: Solid Business Growth at End-September 2024 | SOLID BUSINESS GROWTH AT END-SEPTEMBER 2024 Revenues up +14% to €18.5mOrder book strengthened to €38.3m (+14%) Bezons, October 30, 2024 - 8:00am - RIBER, the global leader for molecular beam epitaxy... ► Artikel lesen |
RIBER receives order to equip an autonomous pilot line for the design and manufacturing of optical devices in Europe | RIBER receives order to equip an autonomous pilot line for the design and manufacturing of optical devices in Europe Bezons (France), September 30, 2024 - 8:00 am (CET) - RIBER, the global leader... ► Artikel lesen |
RIBER: 2024 first-half earnings | 2024 first-half earnings Solid half-year revenues growth (+13%) Gross margin up by 21% and operating income at breakevenNet profit of €0.2m despite the lower seasonal revenues Strong increase in... ► Artikel lesen |